Best of 2021: ProDERM Study: IVIG in Dermatomyositis--The ProDERM study show that IVIg is safe, effective and superior to placebo in patients with dermatomyositis (DM). https://t.co/l15ZLBguxH https://t.co/7s23FeUf5g